Operating Segments (Tables)

6 Months Ended

Jun. 30, 2022

Operating Segments

Schedule of operating segments

	Three Months Ended
	June 30,
	2022		2021
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		228,640		214,824
Total	$	228,640	$	214,824
Loss from Operations
Specialized BioTherapeutics	$	(2,000,350)	$	(1,720,566)
Public Health Solutions		(1,002)		(231,954)
Corporate		(1,393,944)		(1,036,139)
Total	$	(3,395,296)	$	(2,988,659)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,783	$	1,862
Public Health Solutions		463		311
Corporate		5,266		6,667
Total	$	8,512	$	8,840
Other (Expense) Income, Net
Specialized BioTherapeutics	$	68,509	$	41,001
Corporate		(214,908)		185,848
Total	$	(146,399)	$	226,849
Share-Based Compensation
Specialized BioTherapeutics	$	28,343	$	28,731
Public Health Solutions		1,054		7,189
Corporate		42,273		44,701
Total	$	71,670	$	80,621

	Six Months Ended
	June 30,
	2022		2021
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		416,703		362,417
Total	$	416,703	$	362,417
Loss from Operations
Specialized BioTherapeutics	$	(3,540,078)	$	(2,832,974)
Public Health Solutions		(121,623)		(362,735)
Corporate		(3,925,981)		(2,026,557)
Total	$	(7,587,682)	$	(5,222,266)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	5,397	$	3,761
Public Health Solutions		899		627
Corporate		10,448		13,351
Total	$	16,744	$	17,739
Other (Expense) Income, Net
Specialized BioTherapeutics	$	123,588	$	125,635
Corporate		(426,622)		(27,657)
Total	$	(303,034)	$	97,978
Share-Based Compensation
Specialized BioTherapeutics	$	56,847	$	58,310
Public Health Solutions		2,108		13,484
Corporate		90,986		103,632
Total	$	149,941	$	175,426

	As of		As of
	June 30,		December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	167,524	$	128,645
Public Health Solutions		330,545		146,296
Corporate		20,814,385		26,594,986
Total	$	21,312,454	$	26,869,927